Purpose: The pharmacokinetics, pharmacodynamics, and safety of pramlintide and various insulin formulations in patients with type 1 diabetes mellitus (DM) when given as separate injections or ...

α-Glucosidase inhibitors 0.5 0.8 Weight neutral Frequent GI side effects, three times/day dosing, expensive Exenatide 0.5 1.0 Weight loss Injections, frequent GI side effects, expensive, little ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Reactive hypoglycemia is low blood sugar that occurs a few hours after eating a meal. It happens when a person has too much insulin in their blood at the wrong time. Learn more.

metformin — 500mg, 850mg, 1000mg tabs Adults: ≥17yrs: Monotherapy: initially 500mg twice daily or 850mg once daily; may increase by increments of 500mg at 1wk intervals or 850mg in divided ...

Vildagliptin is among a new class of oral diabetes medications currently being studied. The mechanism of these agents involves inhibition of dipeptidyl peptidase IV (DPP4), the enzyme that contributes ...

Five Year View The stage is set for the continued rise in the prevalence of obesity and its associated morbidities. While lifestyle interventions at personal and societal levels are of the utmost ...

For example, thiazolidinediones, insulin, glinides, and sulfonylureas produce weight gain; dipeptidyl peptidase-4 inhibitors are weight neutral; and metformin, pramlintide, exenatide, liraglutide, and ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved non-inferior to daily dosing. The QWINT-1 (NCT05662332), QWINT-3 ...

In type 2 diabetics, the hormone amylin misfolds into amyloid plaques implicated in the destruction of the pancreatic β-cells that make insulin and amylin. The aggregative misfolding of amylin is ...